All filters
Abstracts
COLDA 2020_abstract_79_Aspects psychosociaux de la vie des patients souffrants de l’hépatite virale en Guinée, à propos de 2739 cas
Presented at:
Conference on Liver Disease in Africa (COLDA) 2020
Videos
WHO PMTCT Recommendations - Philippa Easterbrook
Presented at:
Conference on Liver Disease in Africa (COLDA) 2020
Slidesets
Sexual health clinic-based delivery model - Rena Janamnuaysook, MBA
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum - Kristina Brooks, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f) - Paul Domanico, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum - Jeremiah Momper
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Infant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1 - Laura Dickinson
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Low isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment - Marije Van Schalkwyk, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy - Jenna Yager
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
An exploration of adherence measures to detect recent changes in Truvada® dosing patterns - Daijha Anderson
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - Felix Stader
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy - Mary Gockenbach
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir - Aarti Patel
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
CRISPR/Cas and gene editing for HIV - Paula Cannon, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Pharmacological treatment of NASH - Sven Francque, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Population pharmacokinetics of VRC01 in infants and adults - Jerry Li
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Drug-drug interactions: All you need to know beyond www.hiv-druginteractions.org - Marta Boffito, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
50% Adherence is enough with modern ARVS, right - Terrence Blaschke, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
The ‘third wave’ of TB drug development what’s on the horizon (for patients with or without HIV) - Kelly Dooley, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Slidesets
Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine - Anthony Podany, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019